Gene Editing Market is Approximately Hold to Gain at a Impressive CAGR of 18.30% During Forecast 2017-2023
Genetic modification has opened
the doors for reverse genetics, linking of the DNA
sequence to phenotype, and analyzing of gene function. With traditional and
conventional methods becoming obsolete due to its time-consuming, inefficient,
and labor-intensive characteristics, it has led to the emergence of new
technologies and methodologies. Technologies such as TALEN, CRISPR /Cas9
nuclease, and ZFN boast the ability to initiate genome editing in a precise and
easy manner with no limitations by the organism. These advancing technological
instruments have opened new possibilities for conducting large-scale
experiments and added to the market growth of gene editing. The gene editing
method has attained a lot of attention in research institutions and drug
development due to its capability of changing genetic mutations that can cause
diseases. The global gene editing market is forecasted to witness an impressive
rise with a CAGR of 18.30% during the review period of 2018-2023.
The global Gene Editing Market is mainly driven by the growing demand for gene
editing tools from the biotechnology sector, where gene editing is becoming an
increasingly important tool for research of various kinds. The growing gene
editing market is profiled in detail in the report with the help of detailed
information about the market’s historical growth trajectory. This information
provides solid backing for the projections presented in the report for the
market’s likely growth trajectory from 2017 to 2023.
Competitive Analysis:
·
Transposagen
Biopharmaceuticals Inc
·
Thermo Fisher
Scientific Inc
·
Sigma-Aldrich
Corporation
·
Sangamo Biosciences
Inc
·
OriGene Technologies
Inc
·
New England Biolabs
Inc
·
Lonza Group Ltd
·
Integrated DNA
Technologies Inc
Segmentation:
·
The global gene
editing market is segmented on the basis of method, application, end use, and
region.
·
By application, the
global gene editing market is segmented into plant genetic engineering, animal
genetic engineering, microorganism genetic engineering, and gene therapy.
·
By method, the global
gene editing market is segmented into CRISPR, TALEN, ZFN, antisense technology,
and others. CRISPR holds by far the largest share in the global gene editing
market, followed by TALEN. Further enhancements in CRISPR technology to make it
even more precise and useful are likely to further increase the share of the
segment in the coming years.
·
By end use, the
global gene editing market is segmented into the biotech industry, the
pharmaceutical industry, and contract research organizations.
Regional
Analysis:
The
Americas is the highest market share holder in the global geographical
segmentation. The US accounts for the largest contributor to the Americas
market with huge development in drug discovery research, development of the
biotechnology industry, infrastructural superiority in the healthcare industry,
and many other factors.
Europe
closely follows the Americas with the region placing more impetus on finding
better treatment solutions with investments in advancing technologies.
Asia-Pacific is expected to the be fastest growing market due to increasing
support from the government to proliferate the biotechnology sector. Finally,
lack of technical know-how, low level of development in the biotechnology
industry is limiting the growth charts of the Middle East & Africa market.
Comments
Post a Comment